A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy

Area of Science:

• Biochemistry
• Genetics
• Neuroscience
• Endocrinology

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a rare genetic disorder causing adrenal insufficiency and central nervous system (CNS) demyelination.
• X-ALD is characterized by elevated very long chain fatty acids (VLCFAs) due to mutations in the ABCD1 gene, impairing peroxisomal degradation.
• A potential therapeutic strategy involves upregulating the homologous ABCD2 gene to compensate for ABCD1 loss-of-function.

Purpose of the Study:

• To investigate the therapeutic potential of thyroid hormone or sobetirome in a mouse model of X-ALD.
• To determine if pharmacological activation of thyroid hormone receptors can restore VLCFA metabolism.
• To assess the impact on VLCFA levels in the CNS, blood, and peripheral organs.

Main Methods:

• Administration of thyroid hormone or sobetirome (a selective thyroid hormone receptor agonist) to mice with defective Abcd1.
• Measurement of Abcd2 gene expression in the brain.
• Quantification of VLCFA levels in blood, peripheral organs, and brain tissue.

Main Results:

• Sobetirome treatment significantly increased cerebral Abcd2 expression in Abcd1-deficient mice.
• VLCFA levels were reduced in the blood, peripheral organs, and brains of treated mice.
• These findings demonstrate the efficacy of thyromimetic agents in restoring VLCFA homeostasis.

Conclusions:

• Thyroid hormone receptor agonists, like sobetirome, represent a promising therapeutic strategy for X-ALD.
• This approach reactivates VLCFA disposal pathways, addressing the core biochemical defect of the disease.
• Targeting VLCFA metabolism via thyromimetic agents offers a potential treatment for both central nervous system and peripheral manifestations of X-ALD.